The PROVE Registry: Post-market, Real World Evidence With ACURATE neo2
Published: 30 May 2024
-
Views:
1998
-
Likes:
7
-
Views:
1998
-
Likes:
7
Overview
In this insightful interview, Dr Joanna J Wykrzykowska (University of Groningen, Groningen, NL), Prof Holger Thiele (Heart Center Leipzig at University of Leipzig, Leipzig, DE), and Prof Helge Möllmann (St Johannes Hospital, Dortmund, DE) discuss the findings and implications of the PROVE Registry, a comprehensive multi-centre all-comers study focused on the ACURATE neo2 transcatheter aortic valve. The conversation delves into the study's design, key results, and future implications for clinical practice.
The panel discuss the primary and secondary endpoints of the study. The primary endpoint, all-cause mortality at 30 days, was reported at 1.4%, indicating a favourable outcome. Secondary endpoints included technical success, device success, and early safety, with promising results such as a 93.9% technical success rate and 88.0% device success rate. Notably, the incidence of severe paravalvular leak was low, and the mean transvalvular gradient at discharge was significantly reduced at 6.3mmHg and continued to show a low digit single PPI rate of 9.3%.
Overall, the interview provides a comprehensive overview of the PROVE Registry, highlighting its significance in advancing the field of structural heart intervention and improving patient care through evidence-based practices.
Learning Objectives
- Understand the clinical design & goal of the PROVE ACURATE neo2 study
- Review the clinical endpoints and results of the study
- Discover the clinical practice implications of the study
Target Audience
- Interventional Cardiologists
- Cardiac Surgeons
- TAVI Operators
More from this programme
Part 1
The PROVE Registry. Post-market, Real World Evidence With ACURATE neo2
Faculty Biographies
Joanna J Wykrzykowska
Interventional Cardiologist
Dr Joanna J Wykrzykowska obtained her Doctor of Medicine degree from Harvard Medical School and Massachusetts Institute of Technology, Boston MA in 2002. She completed her internal medicine residency at the Massachusetts General Hospital and her Cardiology Fellowship at Beth Israel Deaconess Medical Center (both Harvard teaching hospitals). She continued and completed her Interventional Cardiology fellowship at Erasmus MC, Rotterdam NL in 2010 and obtained her PhD in interventional cardiology in 2011 under the supervision of Prof Patrick Serruys. She worked as staff Interventional Cardiologist at the Amsterdam University Medical Center till 2020 where she was the principal investigator of multiple clinical trials, including AIDA trial (published in NEJM).
Since 2020 Dr Wykrzykowska is an interventional cardiologist and since 2022 holds the title of an Associate Professor of Interventional Cardiology at the University Medical Center in Groningen.
Her research…
Holger Thiele
Professor
Dr Holger Thiele, former director and full professor in the Department of Internal Medicine/Cardiology/Angiology of the University Heart Center Lübeck at the University of Lübeck has been nominated by the faculty of the University of Leipzig as full Professor and Director of the Department of Internal Medicine/Cardiology of the Heart Center Leipzig which is affiliated with the University of Leipzig.
Helge Möllmann
Prof Helge Möllmann is a distinguished cardiologist and the Director of the Clinic for Internal Medicine (Cardiology) at St Johannes Hospital in Dortmund, Germany. With a prolific career in cardiovascular medicine, he has authored over 520 publications, contributing significantly to the advancement of cardiology research and clinical practice.
Prof Helge Möllmann is an esteemed member of several prominent cardiology organisations, including the German Society for Cardiology (DGK) and the Interventional Cardiology Working Group of the DGK. Prof Helge Möllmann's expertise and leadership are further recognised through his roles as a Nucleus member of the European Society of Cardiology (ESC), as well as his involvement in the German Mitral Valve Steering Committee and the German Aortic Valve Executive Board.
Comments